'''Dexfenfluramine''', marketed as '''dexfenfluramine hydrochloride''' under the name '''Redux''', is a [[serotonergic]] [[anorectic]] drug: it reduces appetite by increasing the amount of extracellular [[serotonin]] in the brain.<ref name="stuart">Stuart Ira Fox. Human Physiology. Twelfth Edition. McGraw Hill. 2011. p.665.</ref> It is the d-[[enantiomer]] of [[fenfluramine]] and is structurally similar to [[amphetamine]], but lacks any psychologically stimulating effects.

 
Dexfenfluramine was, for some years in the mid-1990s, approved by the United States [[Food and Drug Administration]] for the purposes of [[weight loss]]. However, following multiple concerns about the cardiovascular side-effects of the drug,<ref name="stuart"/> the FDA withdrew the approval in 1997.<ref>FDA September 15, 1997. [http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)]</ref>  After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by [[sibutramine]], which, although initially considered a safer alternative to both dexfenfluramine and [[fenfluramine]]{{Citation needed|date=July 2011}}, was likewise removed from the US market in 2010.<ref>{{cite news|url=https://www.wsj.com/article/BT-CO-20101008-710904.html |deadurl=yes |archiveurl=https://web.archive.org/web/20101023191137/http://online.wsj.com/article/BT-CO-20101008-710904.html |archivedate=23 October 2010|title=Abbott Pulls Diet Drug Meridia Off US Shelves|date=8 October 2010|newspaper=Wall Street Journal}}</ref>

 
* [https://www.pbs.org/wgbh/pages/frontline/shows/prescription/interviews/lutwak.html Frontline: Dangerous prescriptions] - Interview with Leo Lutwak, M.D. in which he discuses the side effects of fenfluramine, its successor Redux, and the [[Fen-Phen]] combination
